^(131)Ⅰ治疗199例Graves病近期疗效观察

The Short-term Therapeutic Effect of ^(131)Ⅰ in the Treatment of 199 Patients with Graves Disease

目的探讨个体化131Ⅰ剂量治疗Graves病的近期疗效。方法 199例Graves病患者首次采用131Ⅰ治疗,给予个体化治疗剂量,剂量范围在1.60~6.90 MBq/g。随访12个月,随访内容包括症状、体征、血清甲状腺激素及自身抗体、血常规等。结果 199例Graves病患者首次采用131Ⅰ治疗12个月后,痊愈131例(65.8%),好转34例(17.1%),甲状腺功能减退症(甲低)29例(14.6%),无效5例(2.5%)。199例患者中,甲状腺质量<30 g 69例,30~50 g 87例,>50 g 43例,甲状腺质量不同,患者的治愈率(分别为72.5%、63.2%和60.5%)、甲低率(分别为17.4%、17.2%和4.7%)比较,差异均无统计学意义(P>0.05)。结论 131Ⅰ治疗Graves病安全、简便、有效。甲状腺质量不同,131Ⅰ治疗后的治愈率及甲低率无显著差异。

Objective To discuss the short-term efficacy of individual 131Ⅰ dose treatment for the Graves disease.Methods 199 patients with Graves disease were given individual 131Ⅰ dose treatment（between 1.60 to 6.90 MBq/g） for the first time.They were then followed for 12 months,recording their symptoms,signs,serum thyroid hormones and autoantibody,blood and so on.Results After 12 months,199 Graves disease patients who were given individual 131Ⅰ-dose treatment for the first time,131 cases were cured（65.8%）,34 cases improved（17.1%）,29 cases hypothyroidism（referred to as a low）（14.6%）,5 cases ineffective（2.5%）.There were no significant differences in the cured rate（72.5%,63.2%,and 60.5%） and hypothyroidism rate（17.4%,17.2%,and 4.7%） between patients with different thyroid gland weight（P0.05）.Conclusion 131Ⅰ therapy is a safe,simple and the effective method for Graves disease,and no significant difference was shown in therapeutic effect between patients with different thyroid gland weight.